Translocation between chromosomes 9 and 22 lead to the formation of the Philadelphia chromosome which contain the BCR-ABL fusion gene found in most patients with Chronic Myeloid Leukemia (CML) and some patients with Acute Lymphoblastic leukemia (ALL) or Acute Myelogenous Leukemia (AML). The BCR-ABL oncoprotein possessing tyrosine kinase function is responsible for the pathogenesis of CML. Several domains of BCR-ABL protein coordinate, involve and contribute in the pathogenesis of CML. BCR-ABL aberrantly activates multiple signal pathways involving leukemic cell proliferation and survival. Besides GRB2 coupled RAS-MAPK and PI3K/AKT signal pathways, BCR-ABL also activates STAT5 and CRKL signal molecules.
|Tissue Type/Cancer Type|
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 160 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual